Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 9/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313453 | 0.86 | MAP3K11 (0.81) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL13620697 | 0.85 | AXL (0.76) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL8298162 | 0.84 | MAPK8 (0.72) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL8313442 | 0.84 | KIT (0.72) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL14049065 | 0.83 | DYRK1A (0.79) | MAPK8MAPK9MAPK10DYRK1ACLK1 | |
| SCHEMBL8313435 | 0.83 | MAPK8 (0.71) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL8258597 | 0.82 | MAPK8 (0.70) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL8320557 | 0.82 | MAPK8 (0.70) | MAPK8MAPK9MAPK10MAP3K11DYRK1A | |
| SCHEMBL8281299 | 0.82 | MAPK9 (0.69) | MAPK8MAPK9MAPK10MAP3K11KIT | |
| SCHEMBL1487584 | 0.81 | CDK8 (0.72) | MAPK8MAPK9MAPK10MAP3K11KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | MAPK8 26/4885MAPK9 20/4885MAPK10 11/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | MAPK8 33/4885MAPK9 27/4885MAPK10 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.